The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination ...

The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

The funding for Axonis, which is developing novel medicines for pain and epilepsy, reflects growing confidence in precision ...

PumasAI, a science-first organization dedicated to empowering innovation in drug development, today announced the launch of two transformative products: AskPumas and DeepPumas. Representing the ...

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...

Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 ...